Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase Ib, multicenter, single-blinded, placebo-controlled, sequential dose-escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer (LAHNC) receiving induction chemotherapy (ICT). 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Limaye, S. A., Sonis, S. T., Cilli, F., Colevas, A. D., Brennan, M., Hu, K., Haddad, R. I., Murphy, B. A. AMER SOC CLINICAL ONCOLOGY. 2012
View details for Web of Science ID 000318009802371